Belimumab Recombinant Human Monoclonal Antibody, Invitrogen™

Description

• Endotoxin level < 0.01EU/μg by LAL method Use a manual defrost freezer and avoid repeated freeze thaw cycles
• Store at 2 to 8 °C for one week
• Store at -20 to -80 °C for twelve months from the date of receipt
• Belimumab is an intravenous immunosuppressant for the adjunctive treatment of systemic lupus erythematosus (SLE)
• More specifically, it is a fully human recombinant IgG1lambda monoclonal antibody produced from a recombinant NS0 cell line stably transfected with the belimumab heavy chain and light chain genes
• It is the first biological treatment approved for the indication of SLE
• Concomitant use with live or inactivated vaccines must be avoided
• Belimumab was FDA approved on March 9, 2011
• Belimumab consists of 2 heavy chains, and 2 light chains of the lambda subclass
• Each heavy chain contains 452 amino acid residues and each light chain contains 214 amino acid residues
• There are 3 post-translational modifications: a conserved N-linked glycosylation on the CH2 domain at Asn 303 of the heavy chain, the conversion of the N-terminal glutamine residue of the heavy chain into pyroglutamate, and loss of C-terminal lysine residue of the heavy chain.